Hepatitis B usually refers to chronic hepatitis B. Its survival time after the onset of the disease cannot be generalized, and the exact time is related to the degree of liver and kidney damage and whether it is treated in time. Generally speaking, in the absence of cirrhosis, etc., with timely treatment, life expectancy is usually not affected, but if liver function is severely impaired, the survival time of patients can be affected. Chronic hepatitis B can be categorized into mild, moderate and severe according to the severity of the disease. Mild hepatitis B is a milder form of the disease and can be characterized by recurrent symptoms such as weakness, dizziness, loss of appetite, and discomfort in the liver area. Moderate hepatitis B is between mild and severe. As the disease progresses, symptoms of severe hepatitis B such as liver palms, spider nevi and hepatosplenomegaly may appear. Mild hepatitis B generally has a good prognosis. Symptoms can be relieved with prompt and effective treatment, and usually do not affect the patient’s survival time. Severe hepatitis B has a poorer prognosis and may develop cirrhosis or hepatocellular carcinoma with corresponding symptoms of severe impairment of liver function, thus affecting the patient’s life treatment and survival time. For patients with hepatitis B, regular review should be conducted to determine the changes in the condition, and targeted treatment should be given by doctors in order to block its progression to cirrhosis and hepatocellular carcinoma as early as possible, so as to ensure that the quality of life and life expectancy of patients will not be affected.